---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Care management intervention strategies"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Care management intervention strategies. Topics: Team-based care: guideline, Team-based care: meta-analysis and cost-effectiveness, Pharmacist-led management: barbershop trial in Black men, Pharmacist prescribing: US cost-effectiveness, and 3 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Summary

- Team-based care: The 2025 AHA/ACC guideline describes multidisciplinary team-based care, including pharmacists, nurses, and community health workers, as effective in addressing barriers to blood pressure control. In a meta-analysis of 19 studies (5,993 participants), team-based care lowered systolic blood pressure at 12 months by 10.5 mm Hg with non-physician medication titration and 5.0 mm Hg with physician titration compared with usual care; the non-physician titration strategy was estimated at $4,400 per QALY gained over 10 years.
- Pharmacist management: In a cluster-randomized trial of 319 Black men recruited in 52 barbershops, pharmacist-led drug management reduced systolic blood pressure by 21.6 mm Hg more than the control approach at 6 months. A model estimated that 50% uptake of pharmacist prescribing would save $1.137 trillion and 30.2 million life years over 30 years.
- Home blood pressure monitoring and adherence: The guideline states that home blood pressure monitoring improves office blood pressure control when combined with other interventions, and lists dose consolidation, single-pill combinations, pharmacist education, home monitoring with feedback, shared decision-making, and medication synchronization and reminders as evidence-based adherence strategies.

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/); [Victor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6018053/); [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-2.2.2.4-2"></a>

### Team-based care: guideline

> “Multidisciplinary team-based care is effective in assessing and addressing patient access to medications and other structural barriers to support individual patient needs and thereby reduce barriers to achieving hypertension control. Team members may include physicians, pharmacists, nurse practitioners, nurses, physician assistants/associates, dieticians, community health workers, and other health care professionals.”
> “RCTs and meta-analyses of RCTs of team-based hypertension care involving nurse or pharmacist intervention demonstrated reductions in SBP and DBP and/or greater achievement of BP goals when compared with usual care.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-3"></a>

### Team-based care: meta-analysis and cost-effectiveness

> “Among 19 studies comprising 5,993 participants, the 12-month SBP change vs. usual care was −5.0 (95% confidence interval: −7.9 to −2.2) mmHg for TBC with physician titration and −10.5 (−16.2 to −4.8) mmHg for TBC with non-physician titration.”
> “Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.”

Source: [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/)

<a id="topic-2.2.2.4-4"></a>

### Pharmacist-led management: barbershop trial in Black men

> “We enrolled a cohort of 319 black male patrons with systolic blood pressure of 140 mm Hg or more from 52 black-owned barbershops (nontraditional health care setting) in a cluster-randomized trial in which barbershops were assigned to a pharmacist-led intervention (in which barbers encouraged meetings in barbershops with specialty-trained pharmacists who prescribed drug therapy under a collaborative practice agreement with the participants’ doctors) or to an active control approach (in which barbers encouraged lifestyle modification and doctor appointments).”
> “At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).”

Source: [Victor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6018053/)

<a id="topic-2.2.2.4-5"></a>

### Pharmacist prescribing: US cost-effectiveness

> “In this simulated cost-effectiveness analysis of a 5-state Markov model, 50% uptake of a pharmacist-prescribing intervention to improve blood pressure control was associated with a $1.137 trillion in cost savings and could save an estimated 30.2 million life years over 30 years.”

Source: [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-2.2.2.4-6"></a>

### Home blood pressure monitoring

> “Home blood pressure monitoring combined with frequent interactions with multidisciplinary team members using standardized measurement and treatment protocols and home measurement protocols is an important integrated tool to improve rates of blood pressure control.”
> “Among adults taking antihypertensive medication, compared with usual care, HBPM use improves office BP control when used in conjunction with other interventions to lower BP.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-7"></a>

### Adherence interventions

> “Dose consolidation”
> “Single pill combination rather than separate pills”
> “Education/coaching by pharmacists and other health professionals”
> “Electronic/home blood pressure monitoring and feedback”
> “Integration of patient preferences and values/shared decision-making into management plan”
> “Medication synchronization and reminder aids”
> “RCTs, systematic reviews, and meta-analyses provide evidence that the following interventions can improve adherence: medication reminder aids (eg, text, telephone, smartphone apps); patient education and self-management programs”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.4-8"></a>

### Patient-reported needs: dietary counseling and peer education

> “others report that they did not receive dietary counseling and/or referrals to resources such as a registered dietitian or nutritionist to help manage the disease.”
> “Finally, we heard that peer education is important, as peer-to-peer interactions can reinforce physician messages on hypertension treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Shimbo et al. (2020)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000803)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
